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ABSTRACT
The estrogen receptor-a (ERa) knockout mouse (aERKO)
lacks ERa throughout development; therefore, an adult model
for the study of estrogen effects in male mice was recently de-
veloped using the antiestrogen ICI 182,780. However, differenc-
es between species have been noted during immunostaining for
ERa in the male tract as well as in response to treatments with
antiestrogens. Therefore, we developed the antiestrogen model
in the adult male rat to test, in another species, the hypothesis
that estrogen regulates ﬂuid reabsorption in efferent ductules.
Estrogen receptor in the rat was blocked using ICI 182,780 for
100–150 days. Male Sprague-Dawley rats were treated weekly
with s.c. injections of ICI 182,780 (10 mg) or castor oil (as con-
trol).The effects of ICI included testicular atrophy and infertility,
similar to terminal effects in the aERKO male. Additionally, ICI
induced dilations of the rete testis and efferent ductules and a
reduction in the height of the ductule epithelium, which are
changes similar to those in both aERKO and ICI-treated mice.
One difference between species was a large variation in effects
on the rat efferent ductule epithelium, including a transient in-
crease in the number of periodic acid-Schiff-positive, lysosomal-
like granules. These data conﬁrm that estrogen is required for
normal function of the efferent ductules and is essential for
long-term fertility in the male rodent.
epididymis, estradiol receptor, male reproductive tract, mecha-
nisms of hormone action, testis
INTRODUCTION
Estrogen receptor (ER)-a and ERb are present with
overlapping and/or distinct cellular distributions in all or-
gans of the male reproductive system [1–5]. The male
mouse lacking a functional ERa (aERKO) is infertile [6,
7]. The absence of ERb has no apparent effect on male
reproduction, and these mice (bERKO) are fertile [8, 9]. In
agreement with the separate phenotypes for aERKO and
bERKO, the male double knockout (abERKO) is also in-
fertile [9, 10], indicating that ERa has greater importance
in the male reproductive system. The aERKO male has
abnormal rete testes and efferent ductules [11, 12]. The
lumen of these tubules is dilated, and ﬂuid reabsorption is
inhibited [11], which appears to be involved in causing the
infertility.
Because the aERKO mouse lacks ERa throughout de-
velopment, an adult model for the study of estrogen effects
in male mice was recently developed using the antiestrogen
ICI 182,780. After 35 days of treatment, the ICI-treated
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mouse reproduced most of the phenotype seen in the a-
ERKO reproductive tract, except for testicular atrophy and
infertility [13], which raises questions regarding length of
the exposure and whether antiestrogen action is the same
in all species. The mouse has been the species most resis-
tant to the action of antiestrogens having the triphenylethy-
lene formulation, such as tamoxifen [14, 15]. Other species
differences in antiestrogen action have also been reported
[14, 16, 17]. Additionally, differences have been noted be-
tween species during immunostaining for ERa in the male
reproductive tract [1, 18]. Therefore, interspecies differenc-
es in the function of estrogen on male reproduction and
responses to antiestrogen treatment need to be compared.
A comparative analysis of estrogen in rete testis ﬂuid
revealed relatively high concentrations (249 pg ml21) com-
pared to blood levels in the rat [18]. This high concentration
of estrogen in rete testis ﬂuid is consistent with an abundant
expression of ERa protein and mRNA in efferent ductules,
which is 3.5-fold greater than in uterus [2]. Although the
concentration of estradiol and ER are relatively high in the
male rat, we are unaware of any studies examining the ef-
fects of ER disruption on the histology of efferent ductules
in this species. One study looked at the effects of estrogen
and tamoxifen on efferent ductule ﬂuid reabsorption [19],
but those authors did not account for the potential feedback
effects of systemic treatment on the hypothalamus-pitui-
tary-gonadal axis.
The pubertal male rat was treated with the ICI 182,780
(AstraZeneca, Macclesﬁeld, UK), a pure steroidal antiestro-
gen that inhibits both ERa and ERb [20, 21]. Treatment
was given over a long period of time (100–150 days),
which was chosen to investigate whether ER disruption in
the adult rat would result in infertility, as seen in aERKO
mice [6, 7] but not in mice treated with ICI for only 35
days [13]. Because ICI down-regulates the ER and causes
complete abrogation of the ER effects [21–23], the use of
this antiestrogen provides a functional inactivation of ER
similar to that obtained by the genetic knockout of ER ex-
pression [24].
Our results show that ICI treatment promotes adult dys-
functional changes in rat efferent ductules similar to those
of aERKO mice, including the induction of testicular at-
rophy and infertility. The results demonstrate that a func-
tional ER is essential for efferent ductule physiology in the
rat, similar to the mouse. However, in the rat, the efferent
ductule epithelium shows greater variation in morphologi-
cal response than is seen in the aERKO and ICI-treated
mouse models [13].
MATERIALS AND METHODS
Animals
This experiment used 16 outbred, 30-day-old, male Sprague-Dawley
rats purchased from Harlan Bioproducts (Indianapolis, IN). The rats were
maintained under controlled temperature (228C) and lighting (12L:12D).
They were allowed free access to commercial diet (Teklad Chow; Harlan
Teklad, Madison, WI) and tap water. All animal experiments were ap-914 OLIVEIRA ET AL.
TABLE 1. Effects of ICI 182,780 on body, testis, prostate, and seminal vesicle and coagulating gland weights.a
Day Treatment
Weight (g)
Body Testis Ventral prostate
Seminal vesicles 1
coagulating gland
100 Control
ICI 182,780
431.63 6 36.69
394.50 6 17.22
1.88 6 0.15
2.54 6 0.52b
0.67 6 0.18
0.69 6 0.18
1.56 6 0.28
1.69 6 0.20
150 Control
ICI 182,780
448.25 6 6.73
455.48 6 32.88
2.07 6 0.06
1.71 6 0.77
0.88 6 0.28
1.04 6 0.34
1.86 6 0.06
1.73 6 0.53
a Values are mean 6 SEM.
b P , 0.05 vs. control.
FIG. 1. Effects of long-term ICI 182,780 treatment on rat testes. A) This
graph represents individual testis weights for each animal from the ICI-
treated (l) and control (V) groups on the two different days of evaluation.
One testis each from the ICI and control groups is missing on Day 100.
On Day 100, 75% of the ICI-treated testes weighed more than controls,
whereas on Day 150, 75% of the ICI-treated weights were substantially
less than controls, showing that atrophy occurred after Day 100. L, Left
testis; R, right testis. B) The seminiferous tubule diameter was increased
signiﬁcantly (*) on Day 100 in the ICI-treated testes (P , 0.001). Values
represent mean 6 SEM (4.58 and 5.69, control and ICI SEM values, re-
spectively; n 5 3 in each group, from glutaraldehyde-ﬁxed tissues). C)
The luminal area per seminiferous tubule was also increased signiﬁcantly
(*) on Day 100 after ICI treatment. Values represent mean 6 SEM; (n 5
3 in each group, from glutaraldehyde-ﬁxed tissues).
proved by the Laboratory Animal Care Advisory Committee and con-
ducted in accordance with the Guide for the Care and Use of Agricultural
Animals in Agricultural Research and Teaching (http://www.olar.uiuc.
edu).
Treatment
The rats were treated once per week with s.c. injections of ICI 182,780
(AstraZeneca) at a dosage of 10 mg in a volume of 0.2 ml. The control
group received the same volume of castor oil (vehicle). The dose of ICI
182,780 was selected based on the results of a previous dose-response
study, which showed maximum effects on efferent ductules. One group of
matched control and ICI-treated rats (four animals per group) were killed
at 100 days after the ﬁrst injection. However, based on testis weight (the
mean was higher in treated rats than in controls) and fertility results (100%
fertile), it was decided to extend the experiment to 150 days with the
remaining four animals per group.
Breeding
During the treatment period, mating studies were performed to com-
pare the fertility of the ICI-treated and control animals on Days 45, 73,
100, 125, and 150. Males were housed individually with two adult female
Sprague-Dawley, proven breeder rats (Harlan Bioproducts) for a period of
15 days. The females were permitted to adapt to the conditions of the
vivarium for at least 7 days before starting the experiment. They were kept
under the same conditions of light and temperature as the males, and they
received food and tap water ad libitum. At the end of the breeding period
(15 days), the females were killed by an overdose of sodium pentobarbital
(i.p.), and the uterus was examined for pups or implantation sites.
Tissue Preparation
After each treatment period, the rats were anesthetized (i.p. sodium
pentobarbital, 0.1 ml per 100 g body weight), weighed, and perfused in-
tracardially with 4% (w/v) glutaraldehyde in 0.1 M cacodylate buffer (pH
7.4) or neutral buffer formalin. Following perfusion, the testis, reproduc-
tive tract, and accessory glands were removed, immersed in the same
ﬁxative, and stored at 48C. The weights of testes as well as the ventral
prostate and combined seminal vesicles and coagulating gland were re-
corded after ﬁxation. The efferent ductules were dissected away from the
testis and epididymis, and the testis was cross-sectioned at the mid-rete
testis. The testis and efferent ductules were embedded in glycol methac-
rylate resin, sectioned at 2.5-mm thickness, and stained with 1% toluidine
blue or periodic acid-Schiff (PAS) with hematoxylin counterstaining.
Morphometry
Using NIH image software (developed at the U.S. National Institutes
of Health, Springﬁeld, VA; http://rsb.info.nih.gov/nih-image), quantitative
estimations were performed on histological sections obtained from glutar-
aldehyde-ﬁxed tissue. Images were taken using a Spot-2 digital camera
(Diagnostic Instruments, Sterling Heights, MI) mounted on an Olympus
Vanox-T Microscope (Olympus America Inc., Melville, NY) and captured
with a Mac-G3 computer (Apple Computer, Cupertino, CA) using Adobe
Photoshop 5.5 (Adobe Systems, Inc., San Jose, CA). The following pa-
rameters were analyzed: on Day 100 of treatment, seminiferous tubule
diameter and luminal area in 10 randomly selected cross-sections of stages
VII–VIII (measurements were not performed on Day 150, because most
seminiferous tubules were atrophic); luminal diameter of proximal efferent
ductules at the widest region in ﬁve tubule sections; and height of efferent
ductule epithelium from the basement membrane to the microvillus tip, in
areas of straight sections, from 25 cells with evident nuclei.
Statistics
Data from the body and reproductive organ weights (except for testis
weight) as well as the morphometric study were compared using the t-915 ANTIESTROGEN AND MALE FERTILITY
FIG. 2. Morphology of the rat testis after ICI 182,780 treatment. A) Control rat testis and rete testis (RT; outlined with black line). The rete is thin, lying
along the edge of the seminiferous tubules. Bar 5 500 mm. B) ICI-treated testis and rete testis on Day 100. The rete testis (RT; outlined with black line)
is markedly dilated. Bar 5 500 mm. C) ICI-treated testis and rete testis on Day 150. The rete testis (RT; outlined with black line) is markedly dilated,
and the interstitium between seminiferous tubules appear edematous. Bar 5 500 mm. D) Control rat testis. The lumens of the seminiferous tubules are
thin (double arrow). Bar 5 100 mm. E) ICI-treated testis on Day 100. The lumens of the seminiferous tubules are dilated (double arrow). Bar 5 100
mm. F) ICI-treated testis on Day 150. The lumens of the seminiferous tubules are collapsed, and the tubules are atrophic and surrounded by edematous
ﬂuid. Bar 5 100 mm.
FIG. 3. Effects of ICI 182,780 treatment on the rat proximal efferent
ductules (combined period of 100–150 days). A) Luminal diameter of the
efferent ductules was increased 183% in ICI-treated rats compared to con-
trols. Values represent mean 6 SEM (n 5 5, from glutaraldehyde-ﬁxed
tissues). *P , 0.001. B) Efferent ductule epithelial height was decreased
signiﬁcantly after treatment with ICI compared to controls. Values repre-
sent mean 6 SEM (n 5 5, from glutaraldehyde-ﬁxed tissues). *P , 0.001.
test. Testis weights lacked normality of error variances, and the data were
ﬁrst transformed to the Log (10) for analysis by the Welch alternate t-test.
Results are presented as means 6 SEM.
RESULTS
The ICI treatment caused a large variation in testis
weight compared to that of controls, but no signiﬁcant dif-
ference in the weight of the body and secondary sex glands
was found (Table 1). A signiﬁcant increase in testis weight
occurred on Day 100 of ICI treatment (P , 0.05). Treated
rat testes were 35% heavier than those in controls, and they
also showed a signiﬁcant increase in diameter and luminal
areas of seminiferous tubules (Figs. 1 and 2). The luminal
dilation was evident in seminiferous tubules independent of
the cycle stage of the seminiferous epithelium [25]. Sper-
matogenesis appeared to be normal, and degeneration or
sloughing of germ cells was not evident.
On the other hand, on Day 150, a decrease of 33% was
noted in the mean testis weight (P 5 0.065) of the ICI-
treated rats compared to that on Day 100. This decrease in
mean testis weight was seen in all animals, but the effect
was variable, with unilateral and bilateral changes. Testes
weighed as much as 4.46 g and as little as 0.76 g after ICI
treatment, which resulted in a mean difference that was not
statistically signiﬁcant compared to that of controls, even
when the means were transformed. However, 75% of the
testes weighed less than the mean control value (1.71 g).
Histologically, after 150 days of ICI treatment, the semi-
niferous tubules showed atrophy in all testes except for one.
This exception was the testis with the greatest weight (4.46
g), which was due to dilation in seminiferous tubules and
the rete testis, indicating the accumulation of ﬂuid. The
atrophy observed in the remaining testes resulted in re-
duced diameters of seminiferous tubules, with tubules being
dominated by Sertoli cells in most areas (Fig. 2). Occa-
sionally, some tubules exhibited sparse spermatogenic cells,
but normal spermatogenesis was not observed in the atro-
phic testes.
The rete testis (Fig. 2) and efferent ductule lumens in all
treated rats were greatly dilated compared to those in con-
trols. In contrast to aERKO and ICI-treated mice, epithelial
cells ﬁlled with glycogen were not observed at the rete916 OLIVEIRA ET AL.
FIG. 4. Morphology of the rat efferent ductules following ICI 182,780
treatment. A) Control efferent ductules on Day 100. The lumen is narrow,
and the epithelium is tall. Surrounding the ductules is one thin layer of
smooth muscle and large spaces of loose connective tissue. B) ICI-treated
efferent ductules on Day 100. The lumen is dilated (double arrow), and
the epithelium is shorter in height, compared to control (A). The peritu-
bular smooth muscle surrounding the ductules appears thicker than that
in the control. C) ICI-treated efferent ductules on Day 150. The lumen is
dilated (double arrow), and the epithelium is shorter in height compared
to control (A). The peritubular smooth muscle surrounding the ductules
appears thicker than on Day 100 (B). Bar 5 50 mm.
testis-efferent ductule junction. The efferent ductule dila-
tion was more pronounced in the proximal region, where
an increase of 183% was observed (Figs. 3 and 4). Treat-
ment with ICI also caused effects in the efferent ductule
epithelium, the height of which was decreased signiﬁcantly
by 46% (Fig. 3). However, morphology of the epithelial
cells was highly variable (Fig. 5), even in the same efferent
ductule section. On Day 100, some ICI-treated epithelial
cells were columnar, comparable to those in control ani-
mals, whereas other cells were cuboidal in appearance. Var-
iations between these extremes of height were observed
(compare Fig. 5B to 5E). The same variation was found in
the microvillus border and in the presence of endocytotic
vesicles, which were apparently normal in some cells but
shorter, fewer in number, or sometimes missing in others.
On Day 150, variations in the height of epithelium and
microvilli were still present. However, most areas of the
epithelium had decreased height, and microvilli were also
shorter compared to those in controls (compare Fig. 5F to
5I). It was difﬁcult to make a correlation between epithe-
lium and microvillus height, because some taller cells had
reduced microvillus borders and some short cells still re-
tained taller microvilli. At all time periods, lipid droplets
(as identiﬁed by large histological vacuoles) were absent in
the basal cytoplasm of the ICI-treated rats.
The number of PAS-positive, lysosomal-like granules
present in the cytoplasm of nonciliated cells of the efferent
ductules appeared to be increased on Day 100 of ICI treat-
ment (Fig. 5). Also, the position of these granules changed,
from a supranuclear position to a more basal location and
surrounding the nucleus (Fig. 5, B and C). In contrast, on
Day 150, the presence of PAS-positive granules was de-
creased compared with either the control group or with the
Day 100 ICI-treated rats. In ICI-treated animals, some cells
contained large PAS-positive granules, often ﬁlling the en-
tire cytoplasm. The granules appeared to be coalesced,
forming large globules. These cells were mostly basal in
position and had cytoplasmic extensions. Control animals
never displayed these types of cells (Fig. 5A).
Abnormalities in the peritubular basement membrane
area were evident mainly on Day 150 of ICI treatment. The
basement membrane appeared to be thick and irregular
compared to control epithelium. Also, the supporting peri-
tubular cell layer of the efferent ductules was thicker, with
an increased number of smooth muscle cells (Figs. 4 and
5).
The reproductive breeding performance of the ICI-treat-
ed rats was no different from that of the control males
through 100 days of treatment. However, after Day 100, a
signiﬁcant decrease was noted in fertility, with only 50%
fertility on Day 125 and 25% at the end of treatment on
Day 150 (Fig. 6A). The number of pups per male was also
signiﬁcantly decreased on Days 123–150 (Fig. 6B), reveal-
ing subfertility in those ICI-treated males that did breed
successfully.
DISCUSSION
In this study, long-term treatment with ICI 182,780 in
the adult male rat resulted in testicular atrophy and infer-
tility similar to that observed in the aERKO mice [6, 7].
Additionally, morphological characteristics of the efferent
ductules were similar to those observed in the aERKO and
ICI-treated mice [13], including luminal dilation suggestive
of inhibited ﬂuid reabsorption in all models. However, the
differences noted between the ICI-treated mice and rats
may be due to both species and treatment-time differences.
To our knowledge, this is the ﬁrst report of an antiestro-
gen treatment protocol in the male that reproduces the ter-
minal reproductive effects on the testis that were seen in
the aERKO mouse [7, 11, 13]. This study demonstrated
that chemical blockage of ER function in the rat using the
antiestrogen ICI 182,780 resulted in alterations in structure
and function of the male reproductive tract, including: 1) a
transient increase in testis weight; 2) luminal dilation of
seminiferous tubules, rete testis, and efferent ductules; 3)
testicular atrophy; and 4) infertility. These changes rein-
force the importance of a functional ER in the efferent duct-
ules to ensure male fertility. The ICI-rat model also re-
vealed features that were distinct from both the aERKO
and the ICI-mouse models, including: 1) the absence of917 ANTIESTROGEN AND MALE FERTILITY
FIG. 5. Morphology of the rat efferent ductules epithelium after ICI 182,780 treatment. Bar 5 10 mm. A) Control epithelium on Day 100. Nonciliated
cells are columnar in height (double arrow), with tall microvilli (Mv) protruding into the lumen. The PAS-positive, lysosomal-like granules (Ly) are found
in the apical cytoplasm, and lipid droplets (L) are seen in the basal cytoplasm. The peritubular region (P) contains one to two layers of thin smooth
muscle cells. B) ICI-treated rat efferent ductule epithelium on Day 100. Epithelial height is slightly reduced (double arrow) but still columnar and
showing a thick microvillus brush border (Mv). The PAS-positive, lysosomal-like granules (Ly) have moved into the basal cytoplasm around the nucleus.
C) ICI-treated rat efferent ductule epithelium on Day 100. Microvilli are shorter in length, with further reduction in epithelial height (double arrow). D)
ICI-treated rat efferent ductule epithelium on Day 100. The shortened epithelium contains nonciliated cells with longer microvilli (Mv), whereas other
cells have barely detectable microvilli (small arrow). The PAS-positive, lysosomal-like granules are also decreased in number. E) ICI-treated rat efferent
ductule epithelium on Day 100. The epithelial height is very short (double arrow), but some cells still support a small but clear brush border (Mv). The
PAS-positive, lysosomal-like granules are reduced. C, Cilia. F) ICI-treated rat efferent ductule epithelium on Day 150. The epithelium is shorter (double
arrow) than normal but still contains some normal microvilli (Mv). The peritubular area (P) of connective tissue stains dark and is thicker than in the
control (A). G) ICI-treated rat efferent ductule epithelium on Day 150. This epithelium is intermediate in height (double arrow) but has very short
microvilli (small arrow). The peritubular area (P) is amorphous and thick. C, Cilia. H) ICI-treated rat efferent ductule epithelium on Day 150. This
represents a very short epithelium (double arrow). However, these cells sometimes showed normal but short microvilli (small arrow). The peritubular
area (P) stains dark and is thick. I) ICI-treated rat efferent ductule epithelium on Day 150. This is the thinnest (double arrow) epithelium observed, being
approximately 11 mm in height. Nonciliated cells have only a few very short microvilli (small arrow).
cells rich in glycogen at the rete testis-efferent ductule junc-
tion; 2) a transient increase in PAS-positive, lysosomal-like
granules in the nonciliated cells; and 3) greater variation in
efferent ductules epithelium and height of the microvillus
border. Thus, species differences in male reproductive tract
responses to antiestrogen exposure can be detected.
In the present study, a longer treatment period in the rat
resulted in testicular atrophy and infertility, whereas in the
35-day ICI-mouse model, these endpoints were not ob-
served [13]. The most likely reason for this difference is
the length of treatment time. In the mouse, 35 days may
not have been enough time to fully reproduce the aERKO
phenotype. It was fortunate in the present study that treat-
ment was extended beyond 100 days (the original experi-
mental design), because testicular atrophy was not observed
until Day 150. Abnormalities in spermatogenesis were also
delayed. Thus, even the extended period of normal sper-
matogenesis that was found before testicular atrophy in the
aERKO male was replicated in the ICI-treated rat. After
150 days of ICI treatment, the rat testis was decreased in
weight, and seminiferous tubular atrophy was observed,
which correlated directly with the decline in fertility. An
intermediate period of subfertility was seen in the breeding
study at 125 days of treatment. Also, the differences in
testes weights observed within individual ICI-treated ani-
mals on Day 150 were indicative of a gradual atrophy of
the testes. Similar changes were seen in aERKO mice, in
which a transient increase in testis weight at approximately
60–80 days of age preceded the testicular atrophy that oc-
curred during the next 100 days [11]. In both the aERKO
mouse and ICI-rat model, testicular atrophy was a long-
term effect, requiring 150–180 days. Over such a long pe-
riod of time, disturbances in other regions of the male re-
productive tract, such as efferent ductule dilation and loss
of epithelial height, had already occurred. Such ductule
changes were also seen as early as 35 days after treatment
with ICI in the mouse [13].
An increase in testis weight followed by atrophy has
been reported after exposure to several toxicants that affect
the efferent ductules [26–28] as well as after the ligation
of efferent ductules [29]. At ﬁrst, it was thought that the
aERKO male was infertile due to abnormal spermatogen-
esis, and that the epididymis was basically normal [7].
However, a recent study showed that when aERKO germ918 OLIVEIRA ET AL.
FIG. 6. Effects of ICI 182,780 treatment on reproduction in the male rat.
A) In the control group (V), the males showed 100% fertility at all time
points. A decrease in fertility was seen in the ICI-treated group (l) after
Day 100, resulting in only 50% and 25% fertility on Days 123–135 and
135–150, respectively. B) The number of pups per male was also de-
creased after 100 days of ICI treatment, revealing subfertility as well as
infertility. Values represent mean 6 SEM (n 5 4 per group). *P , 0.05.
cells were transplanted into a wild-type testis after depleting
the resident germ cells, the aERKO sperm were capable of
fertilization [30]. These observations in aERKO and ICI-
treated rats suggest that the effects on spermatogenesis, and
the resulting infertility, are not caused by direct effects on
the testis but, rather, by direct effects on the efferent ductule
or epididymis. However, because the Leydig cells are ERa-
positive [1], the possibility remains that some of the ad-
verse testicular effects are due to changes in Leydig cell
function.
Dilation of the proximal efferent ductule lumen in the
ICI-rat model (183% increase) was greater than that in the
aERKO mouse (130%) [12], a response that was also found
in ICI-treated mice compared to aERKO mice of the same
age [13]. This difference has been attributed to develop-
mental overgrowth of the aERKO rete testis, which could
accommodate more ﬂuid and reduce pressure on the effer-
ent ductules [13]. Alternatively, it may be due to less ﬂuid
secretion by the aERKO testis [11]. The effect of ICI treat-
ment on testicular secretions has not been determined as
yet.
Although the efferent ductule epithelium showed an
overall decrease of 46% in height, the ICI-treated rat dis-
played considerable variation in height in both the epithe-
lium and microvillus border. A comparison of efferent duct-
ules from 100 and 150 days in ICI-treated rats showed im-
portant differences in epithelial disruption between the two
time periods. The epithelial variation was more pronounced
on Day 100, when a large number of cells were still normal
in appearance. Although a precise sequence of events lead-
ing to epithelial disruption cannot be described from static
photos, the data suggest that decreases in height of the ep-
ithelium and microvillus border, as well as decreases in
lipid droplets, endocytotic vesicles, and the number of PAS-
positive granules, may be the terminal pathophysiological
events associated with blockage of ER in efferent ductules
of the rat.
Large lipid droplets have been associated with the non-
ciliated cells in the rat efferent ductules [31–33], and they
disappear following ductectomy or ligation [32–34]. Al-
though the signiﬁcance of lipids in these cells is not un-
derstood, several hypotheses have been proposed, including
breakdown products of material taken up by the nonciliated
cells [33]. The disappearance of the lipid in the data pre-
sented here indicates that estrogen is involved in the cel-
lular process that is responsible for the formation of lipid
droplets.
The transient increase and redistribution of the PAS-pos-
itive, lysosomal-like granules in the nonciliated cells of ef-
ferent ductules after ICI treatment was unexpected. In
aERKO and mice treated with ICI for 35 days, these or-
ganelles are decreased to nearly undetectable levels [11,
13]. These granules have been recognized as lysosomes and
appear to be more numerous in rats than in mice [31]. Thus,
this intriguing interspecies difference in lysosomal response
to the antiestrogen should be investigated during future
studies.
The male bERKO mice have no reproductive patholog-
ical phenotype, and these mice are fertile [8, 9]. However,
similar to aERKO mice, the abERKO mice are infertile
[9, 10]. Even though the abERKO male has a grossly nor-
mal reproductive tract [10], these mice exhibited dilation
of the rete testis, loss of germ cells in the seminiferous
tubules [9], and reduced epididymal sperm counts [10].
Considered together, these results suggest that ERa is the
predominant receptor isoform regulating the physiology of
male reproduction. Whether ERb has a speciﬁc function in
the male reproductive tract remains to be determined. The
differences observed between rats and mice following ICI
treatment raise the possibility of differences in the expres-
sion of ER isoforms in the two species. Such a difference
could be important in the study of antiestrogens such as ICI
because of its effects on both receptors [23]. It has been
proposed that in some cells, ERb may be a modulator of
ERa action [35].
To elucidate the role of estrogen in the male, the aro-
matase gene knockout (ARKO) mouse has been proposed
as an alternative model [36–38]. Lacking the enzyme that
converts androgens to estrogens, these mice also experi-
enced a progressive infertility, but impairment of the effer-
ent ductule structure and function was not shown [38, 39].
Even though seminiferous tubule dilation or atrophy have
not been observed in ARKO males, a signiﬁcant decrease
in seminiferous tubule thickness at stage VII has been de-
scribed [38], suggesting that some rete testis ﬂuid might
have been accumulating. On the other hand, rats treated
with an aromatase inhibitor partially resembled the aERKO
mouse and the ICI-treated rat by showing an increase in919 ANTIESTROGEN AND MALE FERTILITY
testis weight. However, the efferent ductules did not show
a consistent response, suggesting that the aromatase inhib-
itor may not have completely inhibited the enzyme in tes-
ticular cells [40]. In any case, ERs are present in ARKO
mice and aromatase inhibitor-treated rats, so the possibility
of nonligand ER transactivation cannot be ignored [41, 42].
With these considerations, several beneﬁts to using the ICI
rather than the inhibiting-aromatase model become appar-
ent, including: 1) as a steroid [21], ICI can probably reach
the cells in the testis and efferent ductules more readily than
a nonsteroidal compound; 2) ICI causes down-regulation of
the ER, avoiding complications induced by other hormones
and other factors [21–23]; 3) ICI does not cross the blood-
brain barrier [43], so it does not interfere with mating be-
havior; and 4) in addition to its antiestrogenic action, ICI
has aromatase-inhibiting effects as well [44]. Overall, the
ICI 182,780 model, in both the mouse and rat, has numer-
ous advantages for the study of estrogen effects on male
reproduction.
In conclusion, as previously shown in mice and now
conﬁrmed in the rat, efferent ductule dysfunction is induced
by the disruption of ER function, which leads to infertility
through mechanisms related to the inhibition of ﬂuid re-
absorption. These data add support to the general hypoth-
esis that estrogen and a functional ERa may be required
for normal fertility in males of all mammalian species.
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